EU Pharma Package hits the final stretch—but can negotiators agree?

With EU trilogues deadlocked over the package, the future of drug exclusivities and access-linked obligations hangs in the balance. Jackie Mulryne and Paul Ranson of Morgan Lewis pinpoint the flashpoints to watch as negotiators push for a year-end deal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

7 January 2026 As he hands over the baton, Bobby Mukherjee reflects on his time leading the Chartered Institute of Patent Attorneys—from progressing the soon-to-be-launched paid apprenticeship schemes to engaging with the UK body’s in-house members. Sarah Speight reports.

Europe

Edwards v Meril: Inside the UPC’s landmark medtech showdown

6 January 2026 As Edwards secures another win against its rival, LSIPR talks to Siddharth Kusumakar—partner at Powell Gilbert and counsel for the winning party.

Europe

Key EU and UK regulatory changes to watch for in 2026

5 January 2026 A number of ongoing legislative processes are likely to significantly impact the life sciences industry this year, writes Jackie Mulryne of Morgan Lewis.

More features

CIPA’s outgoing president: UK rejoining the UPC needs ‘support from business’

Novo Nordisk secures China win ahead of key patent expiration

Edwards v Meril: Inside the UPC’s landmark medtech showdown

Key EU and UK regulatory changes to watch for in 2026

UPC: A review of 2025 and what to expect in 2026

Mental health in IP: ‘We have a clear picture of the problem’

From Edwards to Insulet: Three key medical device cases of 2025

EU unveils sweeping pharma, biotech, and medical device reforms

EU Pharma Package hits the final stretch—but can negotiators agree?

More on this story

Editor's picks

Editor's picks

More features